• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

    3/4/24 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DBVT alert in real time by email

    Montrouge, France, March 4, 2024

    DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

    DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the Company will host a conference call and live audio webcast on Thursday, March 7th, at 5:00 p.m. ET to review full year 2023 financial results and provide a business update.

    Interested participants may access this call via the below teleconferencing numbers and reference the DBV Technologies call:

    United States: 1-844-481-2866

    International: 1-412-317-1859

    A live webcast of the call will also be available under "Events" in the Investors section of the Company's website: https://dbv-technologies.com/investor-overview/events. A replay of the presentation will also be available on DBV's website after the event.

    About DBV Technologies

    DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies' method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies' food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

    Investor Contact

    Katie Matthews

    [email protected]

    Media Contact

    Aurora Krause

    [email protected]

    Viaskin and EPIT are trademarks of DBV Technologies.

    Attachment

    • PDF Version


    Primary Logo

    Get the next $DBVT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DBVT

    DatePrice TargetRatingAnalyst
    5/29/2025$7.25Sell
    Goldman
    1/4/2023Hold → Buy
    Societe Generale
    12/16/2022Neutral → Sell
    Goldman
    5/10/2022$6.00 → $1.50Buy → Neutral
    Goldman
    12/21/2021$8.00 → $5.00Market Outperform
    JMP Securities
    12/21/2021$14.00 → $10.00Buy
    HC Wainwright & Co.
    9/14/2021Hold → Buy
    Societe Generale
    More analyst ratings

    $DBVT
    SEC Filings

    See more
    • SEC Form 8-K filed by DBV Technologies S.A.

      8-K - DBV Technologies S.A. (0001613780) (Filer)

      6/25/25 4:32:27 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by DBV Technologies S.A.

      S-8 - DBV Technologies S.A. (0001613780) (Filer)

      6/24/25 4:06:11 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by DBV Technologies S.A.

      8-K - DBV Technologies S.A. (0001613780) (Filer)

      6/11/25 4:05:24 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Mohideen Pharis sold $730 worth of Ordinary Shares (397 units at $1.84), decreasing direct ownership by 0.36% to 110,113 units (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      5/27/25 4:10:06 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Epic Bpifrance claimed ownership of 10,898,595 units of Ordinary Shares (SEC Form 3)

      3 - DBV Technologies S.A. (0001613780) (Issuer)

      5/20/25 4:01:38 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Bpifrance Investissement S.A.S. claimed ownership of 226,133 units of Ordinary Shares (SEC Form 3)

      3 - DBV Technologies S.A. (0001613780) (Issuer)

      4/24/25 4:01:16 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

      AMF Regulated InformationChâtillon, France, July 28, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2025: 210,069 DBV Technologies shares,€ 171,301.08. When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account: 41,159 DBV Technologies shares,€ 432,367.25. Over the period from January 1, 202

      7/28/25 4:30:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer

      Châtillon, France, July 22, 2025 DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of James Briggs as its Chief Human Resources Officer, succeeding Caroline Daniere. An experienced human capital executive, James will lead key initiatives as DBV transitions from a development-stage biotechnology company to a potential commercial organization. Mr. Briggs will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee. "I want to thank Caroline for her extraordinary leadership and express sincere grati

      7/22/25 4:30:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

      Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc

      6/25/25 4:15:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tasse Daniel bought $14,188 worth of Ordinary Shares (17,094 units at $0.83) (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      3/11/24 4:15:38 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ndu Adora bought $1,624 worth of Ordinary Shares (1,825 units at $0.89) (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      2/8/24 5:02:03 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman resumed coverage on DBV Technologies with a new price target

      Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25

      5/29/25 8:17:33 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies upgraded by Societe Generale

      Societe Generale upgraded DBV Technologies from Hold to Buy

      1/4/23 7:23:06 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies downgraded by Goldman

      Goldman downgraded DBV Technologies from Neutral to Sell

      12/16/22 7:41:19 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Leadership Updates

    Live Leadership Updates

    See more
    • DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer

      Châtillon, France, July 22, 2025 DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of James Briggs as its Chief Human Resources Officer, succeeding Caroline Daniere. An experienced human capital executive, James will lead key initiatives as DBV transitions from a development-stage biotechnology company to a potential commercial organization. Mr. Briggs will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee. "I want to thank Caroline for her extraordinary leadership and express sincere grati

      7/22/25 4:30:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

      Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent

      5/7/24 4:30:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

      Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee. "I am pleased to welcome Virginie to the DBV Executive Committee to lead our global financial organization," said Daniel Tassé, Chief Executive Officer, DBV Tech

      10/16/23 2:00:00 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Financials

    Live finance-specific insights

    See more
    • DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

      Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc

      6/25/25 4:15:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

      Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE    DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FD

      1/8/25 4:05:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

      Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-oldCompany to host investor webcast today at 5:00pm ET DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, tod

      12/11/24 4:05:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      11/14/24 4:55:56 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      2/14/24 8:56:45 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      2/14/24 4:06:12 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care